Holen Sie sich die Stockscreener-App
11.42
0.00%
0.00
Schlusskurs vom Vortag:
$11.42
Offen:
$11.38
24-Stunden-Volumen:
3.33M
Relative Volume:
0.74
Marktkapitalisierung:
$1.23B
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-2.0839
EPS:
-5.48
Netto-Cashflow:
$-382.65M
1W Leistung:
-5.31%
1M Leistung:
+5.16%
6M Leistung:
+18.71%
1J Leistung:
-44.75%
1-Tages-Spanne:
$11.17
$11.64
1-Wochen-Bereich:
$10.88
$12.30
52-Wochen-Spanne:
$5.90
$23.76
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.42 | 1.21B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Polar Asset Management Partners Inc. Sells 250,354 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Zacks Research Has Optimistic Outlook of NTLA Q3 Earnings - MarketBeat
Granahan Investment Management LLC Has $3.38 Million Stake in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Russell Investments Group Ltd. Sells 109,064 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% - AOL.com
Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study - Endpoints News
Intellia Therapeutics (NASDAQ:NTLA) Trading Up 7.5%What's Next? - MarketBeat
Can Traders Expect Breakout From Intellia Therapeutics Inc. This WeekJuly 2025 Rallies & Reliable Volume Spike Trade Alerts - beatles.ru
Real time alert setup for Intellia Therapeutics Inc. performanceJuly 2025 Momentum & Reliable Intraday Trade Plans - Newser
Using data tools to time your Intellia Therapeutics Inc. exitEarnings Overview Report & AI Forecasted Entry and Exit Points - Newser
Signal strength of Intellia Therapeutics Inc. stock in tech scannersQuarterly Trade Summary & Free Verified High Yield Trade Plans - Newser
Intellia Therapeutics, Inc. $NTLA Shares Acquired by PDT Partners LLC - MarketBeat
Is Intellia Therapeutics Inc. stock a smart retirement pickJuly 2025 Gainers & Safe Entry Momentum Stock Tips - خودرو بانک
Armistice Capital LLC Invests $2.59 Million in Intellia Therapeutics, Inc. $NTLA - MarketBeat
What’s next for Intellia Therapeutics Inc. stockMarket Weekly Review & Daily Profit Maximizing Trade Tips - خودرو بانک
Risk Check: Will Intellia Therapeutics Inc. outperform tech stocksQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - خودرو بانک
Is Intellia Therapeutics Inc. benefiting from interest rate changes2025 Retail Activity & Stepwise Swing Trade Plans - خودرو بانک
Is Intellia Therapeutics Inc. building a consolidation basePortfolio Risk Summary & Long-Term Safe Investment Plans - Newser
How hedge fund analytics apply to Intellia Therapeutics Inc. stockTrade Exit Report & Safe Entry Zone Identification - Newser
Will Intellia Therapeutics Inc. stock hit new highs in YEARGlobal Markets & Weekly High Momentum Picks - خودرو بانک
Chart based analysis of Intellia Therapeutics Inc. trendsTrend Reversal & Stepwise Trade Execution Plans - Newser
Published on: 2025-09-05 05:28:03 - Newser
Chart based exit strategy for Intellia Therapeutics Inc.July 2025 Market Mood & Real-Time Stock Movement Alerts - Newser
How to forecast Intellia Therapeutics Inc. trends using time series2025 Price Targets & Free Technical Confirmation Trade Alerts - Newser
Pattern recognition hints at Intellia Therapeutics Inc. upsideLayoff News & Smart Allocation Stock Reports - Newser
ARK Investment Expands Stake in Intellia Therapeutics (NTLA) - GuruFocus
Published on: 2025-09-04 03:41:57 - Newser
Intellia Therapeutics, Inc. $NTLA Holdings Trimmed by Second Line Capital LLC - MarketBeat
Multi asset correlation models including Intellia Therapeutics Inc.2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
Why Intellia Therapeutics Inc. is moving todayTrade Volume Summary & Reliable Volume Spike Trade Alerts - Newser
Is Intellia Therapeutics Inc. stock reversal real or fakeCEO Change & Consistent Profit Trade Alerts - Newser
Cathie Wood’s ARK ETF adjusts portfolio, sells Roku stock, buys CRISPR and Intellia - Investing.com
Panic Selling: Is Intellia Therapeutics Inc. benefiting from interest rate changesJuly 2025 Drop Watch & Verified High Yield Trade Plans - خودرو بانک
Does Intellia Therapeutics Inc. stock have upside surprise potentialJuly 2025 Big Picture & Real-Time Buy Zone Alerts - خودرو بانک
Intellia Therapeutics Inc. stock outlook for YEARPortfolio Growth Summary & Weekly Sector Rotation Insights - Newser
Leading vs lagging indicators on Intellia Therapeutics Inc. performanceWall Street Watch & Fast Gaining Stock Strategy Reports - Newser
What the charts say about Intellia Therapeutics Inc. todayPortfolio Value Report & Stepwise Swing Trade Plans - Newser
Tema Etfs LLC Has $189,000 Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Tools to assess Intellia Therapeutics Inc.’s risk profileQuarterly Trade Report & Expert Verified Stock Movement Alerts - Newser
Merger Talk: Is Intellia Therapeutics Inc. benefiting from interest rate changesEarnings Performance Report & Stepwise Trade Signal Implementation - خودرو بانک
Will Intellia Therapeutics Inc. outperform tech stocksMarket Activity Report & Technical Buy Zone Confirmation - خودرو بانک
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus - Nasdaq
Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider - GlobeNewswire Inc.
Intellia Therapeutics Inc. Stock Flags Risk Zone in Volatility Index getLinesFromResByArray error: size == 0 - thegnnews.com
Aug Levels: What’s next for Intellia Therapeutics Inc. stockInsider Selling & Short-Term Trading Opportunity Alerts - خودرو بانک
Intellia Therapeutics, Inc. $NTLA Shares Acquired by AlphaQuest LLC - MarketBeat
Why is Intellia Therapeutics Inc. stock going upJuly 2025 Update & High Accuracy Trade Signal Alerts - خودرو بانک
Is Intellia Therapeutics Inc. stock good for income investorsPortfolio Performance Report & Consistent Profit Trade Alerts - خودرو بانک
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 23 '25 |
Sale |
14.02 |
7,462 |
104,617 |
106,062 |
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
| GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
| GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
| Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
| Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):